These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12868801)

  • 1. Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy.
    Crown J; Pegram M
    Breast Cancer Res Treat; 2003; 79 Suppl 1():S11-8. PubMed ID: 12868801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
    Slamon D; Pegram M
    Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The platinum agents: a role in breast cancer treatment?
    Crown JP
    Semin Oncol; 2001 Feb; 28(1 Suppl 3):28-37. PubMed ID: 11301372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
    Nabholtz JM; Reese DM; Lindsay MA; Riva A
    Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab/chemotherapy combinations in metastatic breast cancer.
    Ligibel JA; Winer EP
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):38-43. PubMed ID: 12138396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
    Bullock K; Blackwell K
    Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between Herceptin and taxanes.
    Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
    Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
    Burris HA
    Semin Oncol; 2001 Feb; 28(1 Suppl 3):38-44. PubMed ID: 11301373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel in the treatment of breast cancer: an update on recent studies.
    Nabholtz JM; Reese DM; Lindsay MA; Riva A
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):28-34. PubMed ID: 12170449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
    Pegram MD; Pienkowski T; Northfelt DW; Eiermann W; Patel R; Fumoleau P; Quan E; Crown J; Toppmeyer D; Smylie M; Riva A; Blitz S; Press MF; Reese D; Lindsay MA; Slamon DJ
    J Natl Cancer Inst; 2004 May; 96(10):759-69. PubMed ID: 15150304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel-anthracycline combinations in metastatic breast cancer.
    Nabholtz JM
    Breast Cancer Res Treat; 2003; 79 Suppl 1():S3-9. PubMed ID: 12868800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel/trastuzumab combination therapy for the treatment of breast cancer.
    Nabholtz JM; Gligorov J
    Expert Opin Pharmacother; 2005 Aug; 6(9):1555-64. PubMed ID: 16086643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.
    De Laurentiis M; Cancello G; Zinno L; Montagna E; Malorni L; Esposito A; Pennacchio R; Silvestro L; Giuliano M; Giordano A; Caputo F; Accurso A; De Placido S
    Ann Oncol; 2005 May; 16 Suppl 4():iv7-13. PubMed ID: 15923434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ongoing US cooperative group trials using taxanes in the adjuvant setting.
    Davidson NE
    Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S53-8. PubMed ID: 12435293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current status of docetaxel for metastatic breast cancer.
    Esteva FJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):17-26. PubMed ID: 12108894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
    Zhu ZL; Zhang J; Chen ML; Li K
    Asian Pac J Cancer Prev; 2013; 14(12):7111-6. PubMed ID: 24460260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 overexpressing metastatic breast cancer.
    Spigel DR; Burstein HJ
    Curr Treat Options Oncol; 2002 Apr; 3(2):163-74. PubMed ID: 12057079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
    Verma S; Ilersich AL
    Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.